BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34731019)

  • 21. Inhibition growth and metastasis of melanoma by 4-1BBL expressed in normal tissue cells by regulating the function of immune cells.
    Hui Q; Yu X; Hui Z; Zuohua F
    Cancer Biother Radiopharm; 2009 Oct; 24(5):597-605. PubMed ID: 19877890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.
    Labani-Motlagh A; Naseri S; Wenthe J; Eriksson E; Loskog A
    Mol Ther Oncolytics; 2021 Mar; 20():508-518. PubMed ID: 33738337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.
    Martinet O; Ermekova V; Qiao JQ; Sauter B; Mandeli J; Chen L; Chen SH
    J Natl Cancer Inst; 2000 Jun; 92(11):931-6. PubMed ID: 10841829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation.
    Elmetwali T; Salman A; Wei W; Hussain SA; Young LS; Palmer DH
    Sci Rep; 2020 Jan; 10(1):342. PubMed ID: 31941968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
    Kuang Y; Weng X; Liu X; Zhu H; Chen Z; Jiang B; Chen H
    Cancer Lett; 2010 Jul; 293(2):254-62. PubMed ID: 20149524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma.
    Kuriyama H; Fukushima S; Kimura T; Kanemaru H; Miyashita A; Okada E; Kubo Y; Nakahara S; Tokuzumi A; Nishimura Y; Kajihara I; Makino K; Aoi J; Masuguchi S; Tsukamoto H; Inozume T; Zhang R; Nakatsura T; Uemura Y; Senju S; Ihn H
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
    Wenthe J; Eriksson E; Hellström AC; Moreno R; Ullenhag G; Alemany R; Lövgren T; Loskog A
    J Transl Med; 2023 Jul; 21(1):506. PubMed ID: 37501121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L.
    Liu GY; Li ZJ; Li QL; Jin Y; Zhu YH; Wang YH; Liu MY; Li YG; Li Y
    Int Immunopharmacol; 2015 Sep; 28(1):487-93. PubMed ID: 26208317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
    Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
    Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.
    Fontecedro AC; Lutschg V; Eichhoff O; Dummer R; Greber UF; Hemmi S
    Virol J; 2010 Jul; 7():175. PubMed ID: 20670430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
    Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
    J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of a recombinant adenovirus co-expressing truncated human prostate-specific membrane antigen and mouse 4-1BBL genes and its effect on dendritic cells.
    Weng X; Kuang Y; Liu X; Chen Z; Zhu H; Chen H; Jiang B; Shen H
    Braz J Med Biol Res; 2011 Mar; 44(3):186-92. PubMed ID: 21243315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration.
    Kim YM; Kim HK; Kim HJ; Lee HW; Ju SA; Choi BK; Kwon BS; Kim BS; Kim JB; Lim YT; Yoon S
    Exp Mol Med; 2009 Dec; 41(12):896-911. PubMed ID: 19745604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
    Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
    Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
    Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
    Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
    [No Abstract]   [Full Text] [Related]  

  • 37. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
    Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
    Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
    Ylösmäki E; Ylösmäki L; Fusciello M; Martins B; Ahokas P; Cojoc H; Uoti A; Feola S; Kreutzman A; Ranki T; Karbach J; Viitala T; Priha P; Jäger E; Pesonen S; Cerullo V
    Mol Ther Oncolytics; 2021 Mar; 20():459-469. PubMed ID: 33718594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.
    Ramos-Gonzalez MR; Tarique M; Batra L; Arguc F; Garza-Morales R; Shirwan H; Yolcu ES; Gomez-Gutierrez JG
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.